Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330000, China.
Jiangxi Medical College, Nanchang University, Nanchang 330000, China.
Int Immunopharmacol. 2024 Jul 30;136:112369. doi: 10.1016/j.intimp.2024.112369. Epub 2024 Jun 1.
Estrogen and related receptors have been shown to have a significant impact on human development, reproduction, metabolism and immune regulation and to play a critical role in tumor development and treatment. Traditionally, the nuclear estrogen receptors (nERs) ERα and ERβ have been thought to be involved in mediating the estrogenic effects. However, our group and others have previously demonstrated that the G protein-coupled estrogen receptor (GPER) is the third independent ER, and estrogen signaling mediated by GPER is known to play an important role in normal physiology and a variety of abnormal diseases. Interestingly, recent studies have progressively revealed GPER involvement in the maintenance of the normal immune system, abnormal immune diseases, and inflammatory lesions, which may be of significant clinical value primarily in the immunotherapy of tumors. In this article, we review current advances in GPER-related immunomodulators and provide a theoretical basis and potential clinical targets to ameliorate immune-related diseases and immunotherapy for tumors.
雌激素及其相关受体已被证明对人类的发育、生殖、代谢和免疫调节具有重要影响，并在肿瘤的发生和治疗中发挥关键作用。传统上，核雌激素受体（nERs）ERα和 ERβ 被认为参与介导雌激素作用。然而，我们小组和其他小组之前已经证明，G 蛋白偶联雌激素受体（GPER）是第三个独立的 ER，由 GPER 介导的雌激素信号在正常生理和各种异常疾病中发挥重要作用。有趣的是，最近的研究逐渐揭示了 GPER 参与维持正常免疫系统、异常免疫性疾病和炎症病变，这可能具有重要的临床价值，主要是在肿瘤的免疫治疗中。本文综述了与 GPER 相关的免疫调节剂的最新进展，为改善与免疫相关的疾病和肿瘤的免疫治疗提供了理论基础和潜在的临床靶点。
